Executive Officer Notice:

Removal of temporary PINs for Humalog® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog®) is resolved.

September 21, 2023

On March 31, 2023, due to a shortage of the insulin lispro biosimilar Admelog® the ministry listed four additional temporary Product Identification Numbers (PINs) for Humalog® on the Ontario Drug Benefit (ODB) Formulary to provide patients with continued access to insulin lispro through the ODB program. The shortage of the insulin lispro biosimilar (Admelog®) is now resolved and the ministry is **discontinuing** the temporary PINs listed below in the September 2023 Formulary update (effective September 28, 2023).

Temporary PIN	Corresponding DIN/PIN	Product Name	Strength	Dosage Form & Package Size[1]
9858243	2229704	Humalog	100U/mL	Inj Sol-10mL Pk
9858240	2403412	Humalog	100U/mL	Inj Sol-5x3mL Pk
9858241	2470152	Humalog	100U/mL	Inj Sol-Pref Pen 5x3mL Pk (Junior KwikPen)
9858242	9853715	Humalog	100U/mL	Inj Sol-5x3mL Pk

The Ontario government is expanding its biologic drug coverage policy to further promote the use of biosimilars funded through the ODB program. These changes support the ministry's objectives of creating a modern and sustainable drug system that continues to offer high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care. Effective March 31, 2023, the ODB program started transitioning

coverage for the originator biologics Copaxone®[1], Enbrel®, Humalog®[2], Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan® to their biosimilar versions. Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients.

Patients currently using Humalog® should make an appointment with their prescriber to receive a new prescription for Admelog®. Pharmacists are expected to assist patients with their transition to Admelog® now that the supply issues are resolved. More information regarding the biosimilar policy and pharmacists' role in transitioning patients can be found in the Executive Officer Notice: Biosimilar Policy.

This Executive Officer Notice is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators.

Additional Information:

For pharmacies:

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

All other inquiries regarding the biosimilar policy should be directed to DrugProgramsDelivery@ontario.ca

[1] Glatect® and Copaxone® are non-biologic complex drugs (NBCDs), however, the biosimilars policy will apply to their funding. As a result, in this document, references to an originator biologic include Copaxone® and references to a biosimilar include Glatect®.
[2] Humalog® 200 units/mL KwikPen® 200U/mL Inj Sol-Pref Pen 5x3mL Pk (DIN 02439611) is excluded from the biosimilar policy. No biosimilar is available for this strength.